Systematic Review

Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis

Yun Wu †, Li Li †, Di Zhang † and Fei Ma *

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
* Correspondence: drmafei@126.com; Fax: +86-87788060
† These authors contributed equally to this work.

Simple Summary: We performed a systematic review and meta-analysis evaluating the predictive value of the serum HER2 extracellular domain (sHER2 ECD) for breast cancer prognosis. Our review investigated 40 studies (12,229 patients) that assessed the impact of the sHER2 ECD levels on breast cancer prognosis and explored the clinical significance of sHER2 ECD levels in different treatment modalities. Our findings indicated that an elevated sHER2 was an unfavorable prognostic factor in breast cancer. More interestingly, sHER2 ECD was found to be a promising biomarker for predicting adverse clinical outcomes of trastuzumab-based treatment but did not affect the efficacy of tyrosine kinase inhibitors. In addition, the baseline cutoff value of sHER2 ECD in different treatment stages of breast cancer remains to be further explored. Overall, our study suggested that sHER2 ECD levels have important prognostic value in breast cancer and may be helpful for clinicians to select the appropriate anti-HER2 therapy for HER2-positive breast cancer, providing more evidence for guiding clinical practice.

Abstract: An elevated serum HER2 extracellular domain is associated with poor prognosis in breast cancer, but the relationship between sHER2 and the efficacy of different modalities remains controversial. Herein, we aimed to evaluate the prognostic value of serum HER2 extracellular domain (sHER2 ECD) in breast cancer and to identify its correlation with the efficacy of different treatment regimens. A systematic search of the PubMed, Embase, Cochrane Library, Web of Science, and Scopus databases was conducted to identify studies exploring the association between HER2 ECD level and clinical outcomes among patients with breast cancer. Using the random effects models, pooled hazard ratios (HRs), and odds ratios (ORs) with 95% confidence intervals (CI), were calculated for progression-free survival (PFS), overall survival (OS), disease-free survival (DFS), and the objective response rate (ORR). Heterogeneity was further evaluated by subgroup and sensitivity analysis. Overall, 40 studies comprising 12,229 patients were included in this systematic review and meta-analysis. Elevated HER2 ECD levels were associated with worse PFS (HR 1.74, 95% CI 1.40–2.17; p < 0.001), and this effect was observed in patients treated with chemotherapy (HR 1.81, 95% CI 1.37–2.39; p < 0.001), endocrine therapy (HR 1.91, 95% CI 1.57–2.32; p < 0.001), and trastuzumab (HR 1.74, 95% CI 1.31–2.30; p < 0.001). However, this association was not present in patients treated with tyrosine kinase inhibitors (TKIs) (HR 1.44, 95% CI 0.85–2.43; p = 0.17). The HRs/ORs for an elevated HER2 ECD level for DFS, OS, and ORR were 2.73 (95% CI 2.17–3.42; p < 0.001), 2.13 (95% CI 1.77–2.57; p < 0.001), and 0.80 (95% CI 0.49–1.31; p = 0.381), respectively. An elevated sHER2 ECD was an unfavorable prognostic factor in breast cancer but did not affect the efficacy of tyrosine kinase inhibitors such as lapatinib. Detection of sHER2 ECD may be helpful for clinicians selecting the appropriate anti-HER2 therapy for patients with HER2-positive breast cancer.

Keywords: breast cancer; HER2 ECD; prognosis; meta-analysis
1. Introduction

Breast cancer is the most common type of cancer in women worldwide and the leading cause of cancer-related death in females [1]. In 2022, roughly 287,850 new cases of female breast cancer will be diagnosed, and there will be an estimated 43,250 deaths from female breast cancer [2]. Of these, approximately 14% of all cases are classified as the human epidermal growth factor receptor 2 (HER2) positive subtype [2], which is generally associated with a more aggressive and worse prognosis [3]. HER2 is a tyrosine kinase receptor protein with a molecular weight of 185 kDa expressed by a proto-oncogene. Its protein contains three domains, namely the extracellular domain (ECD), the intracellular segment with tyrosine kinase activity, and the transmembrane region [4]. Patients with HER2 overexpression are usually less sensitive to chemotherapy agents; however, the application of therapeutic strategies targeting HER2 has introduced more treatment options for these patients [5–7]. Current anti-HER2 therapy includes a variety of therapeutic regimens, such as monoclonal antibodies, small molecule tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates. However, drug resistance is inevitable during treatment, and exploring biomarkers that can predict the efficacy of different anti-HER2 treatments is an important way to improve the efficacy.

HER2 ECD has been shown to be released into the blood from cancer cells and can be measured in serum [4]. Due to the limitations of subjectivity and hysteresis in the detection of tissue HER2 expression [8] and the fact that serum HER2 ECD (sHER2 ECD) has the advantage of convenience and accessibility, more studies have focused on sHER2 ECD [9,10]. An average of 18.5% of patients with primary breast cancer have elevated sHER2 ECD, compared with approximately 23–80% of patients with metastatic disease [11]. Notably, sHER2 ECD plays multiple roles in assisting diagnosis, facilitating real-time assessment, and evaluating prognosis [11,12]. sHER2 ECD serves as a highly sensitive and specific biomarker for breast cancer screening [13]. More importantly, it has also been shown to be an independent prognostic factor in HER2-positive breast cancer [14]. Different cutoff values have been proposed [15], and sHER2-ECD >15 ng/mL is often used as the positive evaluation standard [14]. An elevated sHER2 ECD has been shown to be associated with poor progression-free survival (PFS), and it was also an unfavorable predictor for anti-HER2 therapy [16]. In addition, Darlix et al. also found that metastatic breast cancer patients with increased sHER2 ECD had a worse prognosis [17]. Despite these promising prospects, the practical application of sHER2 ECD in the management of breast cancer has been hampered by the lack of inconsistent results [18]. Differences in enrolment populations, study designs, detection methodologies, tumor heterogeneity, and cutoff values among different studies may complicate the assessment of its prognostic value [19,20]. It is necessary to synthesize the available evidence from these studies to explore the potential effects of sHER2 ECD levels in patients with HER2-positive breast cancer.

Thus, a systematic review and meta-analysis were performed to evaluate the prognostic impact of baseline sHER2 ECD levels and to further investigate the clinical significance of sHER2 ECD in different treatment modalities, providing more evidence for guiding clinical practice.

2. Materials and Methods

2.1. Systematic Literature Search

This systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines [21]. The study protocol was registered on PROSPERO (Registration Number: CRD42022349499). A comprehensive literature search was performed in the PubMed, Embase, Cochrane Library, Web of Science, and Scopus databases before 11 September 2022. Publications with the following search keywords were included: breast neoplasms, HER2, and extracellular domain. The detailed search strategy is elaborated in Table S1.
2.2. Inclusion and Exclusion Criteria

The inclusion criteria of the present analysis were as follows: (1) Population: female with breast cancer regardless of clinical setting. (2) Intervention: anti-tumor treatment including endocrine therapy, anti-HER2 therapy, and adjuvant therapy. (3) Comparison: comparison of prognosis between patients with elevated sHER2 ECD level or non-elevated sHER2 ECD level. (4) Outcomes: the primary outcomes PFS and the secondary outcomes were disease-free survival (DFS), overall survival (OS), and objective response rate (ORR). The hazard ratio (HR) and 95% confidence interval (CI) for the multiple outcomes should be reported. (5) Study design: randomized controlled trial (RCT), cohort study, and case control study will be included. Exclusion criteria for the study were: (1) non-breast cancer patients; (2) no relevant outcomes; (3) reviews/meta-analyses, letters, comments, editorials or case reports; (4) non-human research studies such as animal or experimental studies; (5) non-English articles.

2.3. Data Extraction and Quality Assessment

Three authors independently (YW, LL, and DZ) conducted the study selection and data extraction, and any discrepancies were resolved through discussion. Certain information was extracted from the qualifying publications: author names, year of publication, ethnicity, sample size, study design (prospective or retrospective), disease status (neoadjuvant, adjuvant, and metastatic), treatment, cutoff values, exposure assessment, and outcomes (ORR, DFS, PFS, and OS). PFS was the primary outcome. DFS, OS, and ORR were the secondary outcomes. Efforts were made to reach the authors in circumstances when the aforesaid information was absent from the articles. The definitions of endpoints were listed as follows: (1) PFS: the time from treatment to progression or death from any cause; (2) OS: the time from surgery or diagnosis to death from any cause; (3) DFS: the time from surgery or diagnosis to relapse or death from any cause; and (4) ORR: the sum of complete and partial response.

The Newcastle–Ottawa Scale (NOS) was used to evaluate the quality of the nonrandomized studies by two authors (YW and LL) independently [22]. Briefly, this system evaluates studies based on the following three domains: selection of participants (4 items); comparability between groups (1 item); and exposure assessment (3 items). Studies with NOS scores of $\geq 7$ were considered high-quality studies, while those with scores less than 7 were assessed as low-quality studies.

2.4. Statistical Analysis

The pooled HR and odds ratios (OR) with 95% CI were calculated for each outcome using the random-effects model. Heterogeneity between the studies was assessed using Cochran’s Q test and $I^2$ statistics. $I^2$ values of $\geq 50\%$ are generally considered to indicate substantial heterogeneity. We performed subgroup analysis to evaluate whether the effects of sHER2 ECD differed for the treatment modalities (endocrine therapy, anti-HER2 therapy, and adjuvant therapy), for the different cutoff values, for disease status (metastatic and (neo)adjuvant disease), and for ethnicity (Caucasian and Ascian). A sensitivity analysis of the investigated outcomes was conducted by sequentially excluding each included study. Funnel plot asymmetry was used to detect publication bias, and Egger’s regression test was applied to assess the funnel plot for significant asymmetry [23]. The “trim and fill” method was used to test and adjust publication bias [24]. Statistical analyses were performed with STATA software (version 17.0; Stata Corporation, College Station, TX, USA). All $p$ values were two-sided, with $p < 0.05$ considered statistically significant.

3. Results

3.1. Eligible Studies

The PRISMA flow diagram of the meta-analysis is shown in Figure 1. A total of 2258 records were identified from the systematic literature review, of which 990 duplicate records were removed. After title and abstract screening of the remaining records, 287 stud-
ies were selected for full-text review. After detailed evaluations, 247 studies were excluded due to outcomes, biomarkers, or other reasons. Eventually, 40 eligible studies were included in this meta-analysis [9,10,13,16,25–60]. The quality assessment of the included studies is summarized in Table S2.

**Figure 1.** Flow diagram illustrating the selection of the included studies.

### 3.2. Study Characteristics

This meta-analysis included 12,229 participants from 40 eligible publications [9,10,13,16,25–60]. The characteristics of the studies are presented in Table 1. The studies were conducted between 2001 and 2021, 28 of which were prospective cohort studies, while the other 12 were retrospective cohort studies. In these studies, the proportion of patients with an elevated sHER2-ECD ranged from 4.40% to 78.99%. A majority of studies (n = 26) defined the cutoff value of an elevated sHER2 ECD level as 15 ng/mL.

There were 13 studies conducted in the (neo)adjuvant stage, 26 in metastatic settings, and the remaining 1 in both the (neo)adjuvant and metastatic phases. Regarding the treatments, 11 studies included patients treated with trastuzumab, 3 studies with patients receiving TKIs, 3 studies with endocrine therapy, and 9 studies with chemotherapy. As for ethnicity, 30 studies were Caucasian, and 10 were Asian.
Table 1. Baseline characteristics of the studies included in the systematic review and meta-analysis.

| Study                  | Year | Sample Size | Elevated (%) | Ethnicity | Study Design | Disease Status | Treatment          | Outcomes | Cutoff of ECD | Exposure Assessment |
|------------------------|------|-------------|--------------|-----------|--------------|----------------|-------------------|----------|--------------|---------------------|
| Banys et al. [26]      | 2017 | 25          | 47.04        | Caucasian | Prospective  | Metastatic     | NA Adjuvant treatment | OS       | 15 ng/mL     | ELISA               |
| Baric et al. [30]      | 2015 | 79          | 44.30        | Caucasian | Retrospective| Adjuvant       | Chemotherapy        | OS       | 15.86 ng/mL  | ELISA               |
| Bewick et al. [59]     | 2001 | 46          | 43.48        | Caucasian | Retrospective| Metastatic     | NA Endocrine therapy | PFS, ORR, OS | 200 U/ml     | ELISA               |
| Bramwell et al. [58]   | 2009 | 158         | 21.52        | Caucasian | Prospective  | Metastatic     | NA                | OS       | 15 ng/mL     | ELISA               |
| Bramwell et al. [58]   | 2009 | 158         | 21.52        | Caucasian | Prospective  | Metastatic     | NA                | OS       | 15 ng/mL     | ELISA               |
| Colomer et al. [25]    | 2007 | 226         | 18.58        | Caucasian | Prospective  | Metastatic     | Chemotherapy ORR   | PFS       | 30 ng/ml     | ELISA               |
| Colomer et al. [52]    | 2004 | 42          | 28.57        | Caucasian | Prospective  | Metastatic     | Chemotherapy ORR   | PFS       | 30 ng/ml     | ELISA               |
| Colomer et al. [42]    | 2006 | 48          | 29.17        | Caucasian | Prospective  | Metastatic     | Chemotherapy ORR   | PFS       | 30 ng/ml     | ELISA               |
| David et al. [45]      | 2008 | 198         | 25.00        | Caucasian | Prospective  | Metastatic     | Chemotherapy ORR   | PFS       | 30 ng/ml     | ELISA               |
| Darlix et al. [41]     | 2016 | 250         | 25.20        | Caucasian | Retrospective| Metastatic     | NA                | OS       | 15 ng/mL     | ELISA               |
| Gioia et al. [60]      | 2015 | 241         | 12.03        | Caucasian | Retrospective| Adjuvant       | Chemotherapy + Trastuzumab | DFS     | 15 ng/mL     | Chemiluminescence   |
| Eppenberger et al. [32]| 2020 | 131         | 67.18        | Caucasian | Prospective  | Metastatic     | Chemotherapy + Trastuzumab | OS, PFS | 15 ng/mL     | Chemiluminescence   |
| Esteva et al. [47]     | 2002 | 30          | 70.00        | Caucasian | Prospective  | Metastatic     | Chemotherapy + Trastuzumab | ORR     | 14.9 ng/mL   | ELISA               |
| Finn et al. [48]       | 2009 | 579         | 16.58        | Caucasian | Prospective  | Metastatic     | Chemotherapy + Trastuzumab | ORR     | 16 ng/ml     | ELISA               |
| Fornier et al. [36]    | 2005 | 55          | 69.09        | Caucasian | Retrospective| Metastatic     | Chemotherapy ORR   | ORR      | 15 ng/mL     | Chemiluminescence   |
| Im et al. [40]         | 2005 | 27          | 14.81        | Asian     | Prospective  | Metastatic     | Chemotherapy ORR   | ORR, OS  | 15 ng/ml     | ELISA               |
| Jensen et al. [33]     | 2003 | 100         | 32.00        | Caucasian | Prospective  | Metastatic     | Chemotherapy PFS   | ORR, OS  | 15 ng/ml     | ELISA               |
| Knuston et al. [54]    | 2014 | 54          | 55.56        | Caucasian | Prospective  | Metastatic     | Chemotherapy + Trastuzumab | PFS     | 15 ng/mL     | ELISA               |
| Kong et al. [46]       | 2012 | 252         | 15.08        | Asian     | Prospective  | Adjuvant       | Chemotherapy + Trastuzumab | DFS, ORR | 15 ng/mL     | Chemiluminescence   |
| Kontani et al. [35]    | 2013 | 19          | 63.16        | Asian     | Prospective  | Metastatic     | Chemotherapy + Trastuzumab | ORR     | 15.2 ng/mL   | Chemiluminescence   |
| Kostler et al. [34]    | 2004 | 55          | 72.73        | Caucasian | Prospective  | Metastatic     | Chemotherapy ORR   | ORR      | 15 ng/mL     | ELISA               |
| Lee et al. [56]        | 2016 | 436         | 11.93        | Asian     | Retrospective| Adjuvant       | Adjuvant treatment | DFS     | 15 ng/mL     | Chemiluminescence   |
| Lee et al. [57]        | 2014 | 2862        | 4.40         | Asian     | Retrospective| Adjuvant       | Adjuvant treatment | DFS     | 15 ng/mL     | Chemiluminescence   |
| Lipton et al. [44]     | 2002 | 719         | 30.46        | Caucasian | Retrospective| Metastatic     | Endocrine therapy ORR, ORR, PFS | 15 ng/mL | ELISA               |
| Lipton et al. [27]     | 2003 | 562         | 29.18        | Caucasian | Prospective  | Metastatic     | Endocrine therapy ORR, PFS | 15 ng/mL | ELISA               |
### Table 1. Cont.

| Study                  | Year | Sample Size | Elevated (%) | Ethnicity | Study Design | Disease Status | Treatment | Outcomes | Cutoff of ECD | Exposure Assessment          |
|------------------------|------|-------------|--------------|-----------|--------------|----------------|-----------|----------|----------------|-------------------------------|
| Lipton et al. [10]     | 2011 | 138         | 78.99        | Caucasian | Prospective  | Metastatic     | TKIs      | PFS      | 15 ng/mL      | ELISA                         |
| Ludovini et al. [38]   | 2008 | 256         | 8.98         | Caucasian | Prospective  | Adjuvant       | Adjuvant treatment | OS, DFS | 15 ng/mL      | Chemiluminescence/ELISA       |
| Luftner et al. [53]    | 2004 | 35          | 62.86        | Caucasian | Prospective  | Metastatic     | Chemotherapy | ORR, PFS | 15 ng/mL      | ELISA                         |
| Molina et al. [37]     | 2010 | 275         | 14.91        | Caucasian | Prospective  | Adjuvant       | Adjuvant treatment | DFS     | 15 ng/mL      | ELISA                         |
| Moreno-Aspitia et al.  | 2013 | 2318        | 37.41        | Caucasian | Retrospective| Adjuvant       | Chemotherapy + Trastuzumab | DFS     | 15 ng/mL      | Chemiluminescence             |
| Muller et al. [49]     | 2004 | 103         | 35.92        | Caucasian | Retrospective| (Neo)adjuvant/ | Chemotherapy + Trastuzumab | ORR, PFS, OS | 15 ng/mL      | ELISA                         |
| Reix et al. [13]       | 2016 | 334         | 15.27        | Caucasian | Prospective  | Metastatic     | Chemotherapy + Trastuzumab | DFS, PFS, OS | 15 ng/mL      | ELISA                         |
| Ryu et al. [50]        | 2012 | 200         | 7.00         | Asian     | Prospective  | Adjuvant       | Adjuvant treatment | DFS     | 15 ng/mL      | Chemiluminescence             |
| Sandri et al. [28]     | 2004 | 39          | 10.26        | Caucasian | Prospective  | Metastatic     | Chemotherapy | PFS, OS | 15 ng/mL      | Chemiluminescence             |
| Shao et al. [31]       | 2014 | 62          | 41.94        | Asian     | Prospective  | Metastatic     | Chemotherapy + Trastuzumab | PFS, ORR | 15 ng/mL      | Chemiluminescence             |
| Tchou et al. [29]      | 2015 | 118         | 22.88        | Caucasian | Prospective  | Adjuvant       | Adjuvant treatment | DFS     | 7 ng/mL       | ELISA                         |
| Thureau et al. [51]    | 2012 | 65          | 10.77        | Caucasian | Retrospective| Adjuvant       | Chemotherapy + Trastuzumab | DFS, OS | 15 ng/mL      | ELISA                         |
| Tsai et al. [55]       | 2012 | 185         | 12.43        | Asian     | Prospective  | Adjuvant       | Adjuvant treatment | DFS, OS | 8.9 ng/mL     | ELISA                         |
| Wang et al. [16]       | 2016 | 546         | 43.22        | Asian     | Prospective  | Metastatic     | NA         | PFS      | 15 ng/mL      | Chemiluminescence             |
| Witzel et al. [39]     | 2006 | 76          | 39.47        | Caucasian | Prospective  | Metastatic     | NA         | PFS, OS  | NA             | NA                            |
| Zuo et al. [43]        | 2021 | 309         | 53.07        | Asian     | Retrospective| Neoadjuvant    | Chemotherapy + Trastuzumab | DFS     | 15 ng/mL      | Chemiluminescence             |

Abbreviations: ORR, overall response rate; DFS, disease-free survival; OS, overall survival; PFS, progression-free survival; NA, not available; ELISA, enzyme-linked immunosorbent assay.
3.3. Progression-Free Survival

A total of seventeen studies (n = 3662) reported the correlation between the sHER2 ECD level and PFS [10,13,16,25,27,28,31–33,39,44,45,48,49,53,54,59]. Between the studies, significant heterogeneity was seen with an $I^2$ index of 91.2% ($p < 0.001$). The pooled analysis results indicated that an elevated sHER2 ECD level was significantly associated with shorter PFS (HR 1.74; 95% CI 1.40–2.17; $p < 0.001$; Figure 2) using the random-effects method. According to the sensitivity analysis, serial exclusion of studies was not significantly associated with the point estimates of pooled HRs for PFS (range, 1.68–1.80). Taking account of the excluded studies (Figure S1a), the pooled HRs remained statistically significant. This suggested that the pooled results were not affected by any of the single studies included and that this meta-analysis had relatively stable results.

![Figure 2. Forest plot of the HR for the PFS from the eligible studies [10,13,16,25,27,28,31–33,39,44,45,48,49,53,54,59].](image)

Subgroup analysis was performed according to different treatment modalities and cutoff values (Table 2). Interestingly, elevated levels of sHER2 ECD were significantly associated with poor clinical outcomes in patients treated with chemotherapy (pooled HR = 1.81, 95% CI 1.37–2.39, Figure S2a), endocrine therapy (pooled HR = 1.91, 95% CI 1.57–2.32), and trastuzumab administration (pooled HR = 1.74, 95% CI 1.31–2.30). However, no such association was found in patients treated with TKIs (pooled HR = 1.44, 95% CI 0.85–2.43). As for different cutoff values, the prognostic significance could also be seen in the 15 ng/mL ($p < 0.001$), 15–20 ng/mL ($p < 0.001$), and 2500 U/mL ($p = 0.011$) group (Figure S2b). Furthermore, the same result was also observed in Caucasians (pooled HR = 1.71, 95% CI 1.36–2.16) and Asians (pooled HR = 1.93, 95% CI 1.18–3.17) (Figure S2c).
| Categories                                | No. of Studies | No. of Patients | Pooled HR (95% CI) | Heterogeneity | No. of Studies | No. of Patients | Pooled HR (95% CI) | Heterogeneity |
|-------------------------------------------|----------------|----------------|-------------------|---------------|----------------|----------------|-------------------|---------------|
|                                           |                |                | Random p-Value     | I² (%) p-Value|                |                | Random p-Value     | I² (%) p-Value |
| All patients                              | 17             | 3662           | 1.74 (1.40–1.72)  | <0.001        | 91.2           | <0.001        | 13                | 2.31 (1.94–2.75) |
| Treatment                                 |                |                |                   |               |                |                |                   |               |
| Chemotherapy                              | 6              | 611            | 1.81 (1.37–2.39)  | <0.001        | 1.8            | 0.366         | 1                 | 1.81 (1.26–2.61) |
| Endocrine therapy                         | 3              | 1507           | 1.91 (1.57–2.32)  | <0.001        | 59.2           | 0.086         | 1                 | NA            |
| TKIs                                      | 3              | 627            | 1.44 (0.85–2.43)  | 0.17          | 82.2           | 0.004         |                   |               |
| Trastuzumab + Chemotherapy                | 4              | 295            | 1.74 (1.31–2.30)  | <0.001        | 24.3           | 0.265         | 5                 | 3.25 (1.98–5.31) |
| Adjuvant therapy                          |                |                |                   |               |                |                |                   |               |
| Cutoff value                              |                |                |                   |               |                |                |                   |               |
| 15 ng/mL                                  | 12             | 2537           | 1.64 (1.27–2.11)  | <0.001        | 92.2           | <0.001        | 12                | 2.68 (2.11–3.41) |
| 5–10 ng/mL                                |                |                |                   |               |                |                |                   |               |
| 15–30 ng/mL                               | 3              | 805            | 2.65 (1.97–3.56)  | <0.001        | 0              | 0.928         | 1                 | 3.58 (1.65–7.76) |
| 82 ng/mL                                  | 1              | 198            | 1.50 (0.92–2.45)  | 0.105         | -              | -             |                   |               |
| 2500 U/mL                                 | 1              | 46             | 2.33 (1.22–4.46)  | 0.011         | -              | -             |                   |               |
| Disease status                            |                |                |                   |               |                |                |                   |               |
| Metastatic                                | 18             | 3662           | 1.74 (1.40–2.17)  | <0.001        | 91.2           | <0.001        | 13                | 2.73 (2.17–3.42) |
| (Neo)adjuvant                             |                |                |                   |               |                |                |                   |               |
| Ethnicity                                 |                |                |                   |               |                |                |                   |               |
| Caucasian                                 | 16             | 3054           | 1.71 (1.36–2.16)  | <0.001        | 91.2           | <0.001        | 7                 | 2.59 (1.88–3.57) |
| Asian                                     | 2              | 608            | 1.93 (1.18–3.17)  | 0.009         | 43.8           | 0.182         | 6                 | 2.95 (2.13–4.07) |

TKI, tyrosine kinase inhibitor; DFS, disease-free survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.
3.4. Disease-Free Survival

Thirteen studies with a total of 7599 patients offered adequate data for DFS analysis \([9,13,29,37,38,43,46,50,51,55–57,60]\). The pooled HR was 2.31 (95% CI 1.94–2.75, \(p < 0.001\), Figure 3), suggesting that a high level of sHER2 ECD is highly correlated with poor DFS. There was no evidence of statistically significant heterogeneity between studies (\(I^2 = 25.5\%; p = 0.187\)). In the sensitivity analysis, the pooled HR estimates for DFS were not affected after excluding each study (Figure S1b). The subgroup analysis revealed an association between an elevated sHER2 ECD level and a shorter DFS in all subsets (Table 2, Figure S3).

3.5. Overall Survival

A total of 20 studies, involving 5963 patients, provided applicable data for OS analysis \([13,25,26,28,30,32,33,38–41,44,46,49,51,54,55,57–59]\). As the heterogeneity among these studies showed statistical significance (\(I^2 = 48.4\%; p = 0.008\)), the random-effect model was employed to estimate the pooled HR (HR = 2.13, 95% CI 1.77–2.57, \(p < 0.001\), Figure 4). The results demonstrated that an elevated sHER2 ECD was significantly associated with unfavorable OS in breast cancer patients. In addition, after the sequential exclusion of each study from the pooled analysis, the conclusion was not changed (Figure S1c). The results of each subgroup analysis that included different cutoff values, treatment modalities, ethnicities, and disease status were generally consistent with the entire patient cohort (Table 3, Figure S4).

![Figure 3. Forest plot of the HR for the DFS from the eligible studies [9,13,29,37,38,43,46,50,51,55–57,60].](image-url)
| Categories                   | No. of Studies | No. of Patients | Pooled HR (95% CI)          | Heterogeneity | No. of Studies | No. of Patients | Pooled or (95% CI)       | Heterogeneity |
|------------------------------|----------------|----------------|-----------------------------|---------------|----------------|----------------|--------------------------|---------------|
|                             |                |                | Random p-Value I² (%) p-Value |               |                |                | Random p-Value I² (%) p-Value |               |
| OS                           |                |                |                             |               |                |                |                           |               |
| All patients                 | 20             | 5963           | 2.13 (1.77–2.57) <0.001 48.4% 0.008 |               | 14             | 2274           | 0.80 (0.49–1.31) 0.381 73 < 0.001 |               |
| Treatment                    |                |                |                             |               |                |                |                           |               |
| Chemotherapy                 | 5              | 315            | 2.19 (1.60–3.01) <0.001 0 0.817 |               | 7              | 605            | 0.69 (0.38–1.26) 0.225 43.6 0.1 |               |
| Endocrine therapy TKIs       | 2              | 945            | 2.67 (1.44–4.97) 0.002 75.1 0.045 |               | 3              | 1507           | 0.37 (0.28–0.49) <0.001 0 0.988 |               |
| Trastuzumab + Chemotherapy   | 4              | 584            | 2.00 (1.02–1.95) 0.045 76.8 0.005 |               | 4              | 159            | 5.50 (1.15–26.21) 0.033 0.035 65 |               |
| Adjuvant therapy             | 5              | 3382           | 2.56 (1.75–3.74) <0.001 0 0.896 |               |                |                |                           |               |
| Cutoff value                 |                |                |                             |               |                |                |                           |               |
| 15 ng/mL                     | 14             | 5101           | 1.98 (1.59–2.48) <0.001 51.1 0.014 |               | 10             | 1667           | 1.02 (0.53–1.97) 0.985 76.4 < 0.001 |               |
| 5–10 ng/mL                   | 1              | 185            | 3.22 (1.43–7.26) 0.005 NA NA |               |                |                |                           |               |
| 15–30 ng/mL                  | 3              | 555            | 2.99 (2.09–4.29) 0.001 0 0.523 |               | 3              | 847            | 0.46 (0.16–1.29) 0.138 73.7 0.022 |               |
| 50 ng/mL                     | 1              | 46             | 2.36 (1.21–4.62) 0.012 NA NA |               | 1              | 48             | 1.06 (0.30–3.71) 0.924 NA NA |               |
| 2500 U/ml                    |                |                |                             |               |                |                |                           |               |
| Disease status               |                |                |                             |               |                |                |                           |               |
| Metastatic (Neo)adjuvant     | 13             | 2182           | 1.94 (1.58–2.38) <0.001 54.8 0.009 |               | 13             | 2562           | 0.80 (0.49–1.31) 0.381 73 < 0.001 |               |
| Metastatic and (Neo) adjuvant| 6              | 3447           | 2.78 (1.92–4.01) 0.001 0 0.605 |               |                |                |                           |               |
| Ethnicity                    |                |                |                             |               |                |                |                           |               |
| Caucasian                    | 16             | 2889           | 2.07 (1.68–2.55) <0.001 55.2 0.004 |               | 11             | 2166           | 0.74 (0.46–1.20) 0.220 71.0 < 0.001 |               |
| Asian                        | 4              | 3074           | 2.58 (1.71–3.90) <0.001 0 0.689 |               | 3              | 108            | 2.63 (0.11–63.22) 0.522 85.2 0.001 |               |

TKI, tyrosine kinase inhibitor; ORR, overall response rate; OS, overall survival; HR, hazard ratio; OR, odd ratio; CI, confidence interval.
3.6. Objective Response Rate

Funnel plots were generated to detect potential publication bias (Figure S6b–d), which did not reveal remarkable asymmetry for DFS, OS, and ORR. In the PFS analysis, the funnel plot showed the asymmetric distribution of studies, and Egger’s test was significant ($p < 0.001$; Figure S6a), suggesting that some publication bias might be present. Ten necessary studies were found missing by the “trim and fill” method. After filling in these ten with comprehensive analysis, the funnel plot regained symmetry (Figure S7). With the trim-and-fill approach, the imputed estimate HR and 95% CI was 1.65 (1.34 to 2.03), suggesting that publication bias should be considered, but it was not a major influencing factor for the intervention effect. In other words, the major outcomes were not affected by publication bias.

4. Discussion

Currently, a variety of monoclonal antibodies, TKIs, and antibody-drug conjugates have been approved for HER2-positive breast cancer, providing more options for these patients. However, there are few biomarkers for efficacy prediction and prognostic assessment in HER2-positive breast cancer. Some studies have shown that high-level sHER2 ECD was associated with significantly poor prognosis [47], but other studies could not confirm this finding [48]. To our knowledge, this is the first meta-analysis to explore the relationship between sHER2 ECD and different treatment regimens in breast cancer. Our results demonstrated that high levels of sHER2 ECD can be used as a biomarker for predicting a poor response to chemotherapy, endocrine therapy, and trastuzumab-targeted therapy, but they did not affect the efficacy of TKIs.

Our findings indicated that elevated sHER2 ECD was associated with poor clinical outcomes, which were consistent with the results of some previously published studies [19,26,60,61]. For example, in a large sample retrospective study of 2862 patients, elevated sHER2 ECD was an independent prognostic factor for worse distant-metastasis-free survival and breast-cancer-specific survival [57]. Moreover, in a study by Moreno et al [9], patients were randomly assigned to arms A (standard chemotherapy), B
(standard chemotherapy with sequential trastuzumab), and C (standard chemotherapy with concurrent trastuzumab). The results showed that patients with baseline sHER2 levels \( \geq 15 \text{ ng/mL} \) had worse DFS than those with baseline sHER2 levels <15 ng/mL (arm A: HR, 1.81; \( p = 0.0014 \); arm B: HR, 2.08; \( p = 0.0015 \); arm C: HR, 1.96; \( p = 0.01 \)) [9]. Additionally, for patients with metastatic breast cancer, an elevated ECD was significantly associated with decreased PFS and OS [16,25,32]. Of note, in our analysis, the baseline sHER2 ECD was not related to the ORR in the overall population. However, in the subgroup receiving endocrine therapy, patients with low sHER2 ECD levels had a higher ORR. A study by Colomer et al. showed that in patients with metastatic breast cancer treated with letrozole, the ORR was lower in the group with elevated HER2 ECD levels (14% vs. 30%; \( p < 0.036 \)) [25]. Similarly, in another study of patients treated with letrozole and tamoxifen, elevated serum HER-2/neu was a negative predictor for ORR and time to progression [27].

The value of 15 ng/mL was the cutoff for sHER2 ECD in most studies, but higher cutoff values were also found in some studies, especially in those for metastatic breast cancer [42,52]. In the current study, different cutoff values for sHER2 ECD were explored, with consistent results. It should be emphasized, however, that sHER2 ECD levels vary greatly in different stages of breast cancer. Among patients with early-stage breast cancer, only 4%-10% had sHER2 ECD levels greater than 15 ng/mL [31,57], while 20%-80% of patients with metastatic breast cancer had an sHER2 ECD above 15 ng/mL [26–28,34]. Furthermore, the level of sHER2 ECD exhibited dynamic changes during treatment and disease progression. Metastatic breast cancer patients with decreased sHER2 ECD tend to have longer PFS [48,62]. In addition, sHER2 ECD levels were higher in patients with tissue HER2-positive, ER-negative, axillary lymph node, and distant metastases [50].

We performed a subgroup analysis to evaluate whether the effects of the sHER2 ECD differed for the treatment modalities. In the subgroup analysis of different treatment regimens, patients receiving trastuzumab with high sHER2 ECD had worse DFS, PFS, and OS levels than those with low sHER2 ECD levels. Similar results were obtained in the subgroup receiving chemotherapy. Interestingly, however, levels of sHER2 ECD were not associated with PFS and OS in TKI-treated patients. An elevated baseline sHER2 ECD implied resistance to trastuzumab but did not predict the response to lapatinib [45]. Lee et al reported that elevated sHER2 ECD predicted greater PFS benefit with lapatinib independent of sHER2 status [63]. The above evidence suggests that TKIs may overcome the drug resistance and disease progression caused by HER2 ECD shedding. A constitutively active truncated receptor, p95 HER2, is left by ECD shedding in the membrane, and it is 10-100-fold more oncogenic than the full-length receptor [4]. Cleavage of the ECD from HER2 loses the target that trastuzumab and pertuzumab bind to, while it significantly increases the tyrosine kinase activity of the truncated receptor and substantially enhances its transforming potential, which may be the mechanism by which the efficacy of TKIs is not affected. Therefore, the sHER2 ECD level may help clinicians select the appropriate anti-HER2 therapy for patients with HER2-positive breast cancer.

As a meta-analysis, there were limitations to our study. First, the funnel plot analysis of PFS showed an asymmetric distribution, implying the existence of publication bias. Second, the number of studies using TKIs as treatment regimens was relatively small. Prospective clinical studies with larger samples are needed for further validation. Despite these limitations, this systematic review and meta-analysis revealed that sHER2 ECD is an important prognostic factor for DFS, PFS, and OS in breast cancer patients and found that TKIs can overcome the adverse effects of elevated sHER2 ECD.

5. Conclusions

In summary, this systematic review and meta-analysis showed that elevated sHER2 ECD levels might be a prognostic indicator for reduced DFS, PFS, and OS. However, elevated sHER2 ECD levels did not affect the efficacy of TKIs. The baseline cutoff value of sHER2 ECD in different treatment stages of breast cancer needs to be further explored, and
the combination of multi-node dynamic monitoring is more conducive to monitoring the treatment efficacy and predicting the prognosis of patients.

**Supplementary Materials:** The following supporting information can be downloaded at: [https://www.mdpi.com/article/10.3390/cancers14194551/s1](https://www.mdpi.com/article/10.3390/cancers14194551/s1). Table S1. Full search strategy in PubMed (a), Embase (b), the Cochrane Library (c), Web of Science (d) and Scopus (e). Table S2. Newcastle—Ottawa Quality Assessment form for non-randomized studies. Figure S1. Sensitivity analysis for PFS (a), DFS (b), OS (c), and ORR (d). Figure S2. Subgroup analysis of PFS according to different treatment modalities (a), cut-off values (b) and ethnicity (c). Figure S3. Subgroup analysis of DFS according to different treatment modalities (a), cut-off values (b) and ethnicity (c). Figure S4. Subgroup analysis of OS according to different treatment modalities (a), cut-off values (b), disease status (c) and ethnicity (d). Figure S5. Subgroup analysis of ORR according to different treatment modalities (a), cut-off values (b) and ethnicity (c). Figure S6. Funnel plot to detect publication bias for PFS (a), DFS (b), OS (c), and ORR (d). Figure S7. Trim and fill analysis for pooled HR of PFS.

**Author Contributions:** Y.W., L.L. and D.Z.: protocol development, data extraction, data analysis, and manuscript writing. F.M.: protocol development and final manuscript review. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 2018, 68, 394–424. [CrossRef]

2. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Female Breast Cancer. Available online: [https://seer.cancer.gov/statfacts/html/breast.html](https://seer.cancer.gov/statfacts/html/breast.html) (accessed on 31 July 2020).

3. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987, 235, 177–182. [CrossRef]

4. Perrier, A.; Gligorov, J.; Lefèvre, G.; Boisson, M. The extracellular domain of Her2 in serum as a biomarker of breast cancer. *Lab. Invest.* 2018, 98, 696–707. [CrossRef] [PubMed]

5. Arteaga, C.L.; Slawkowsi, M.X.; Osborne, C.K.; Perez, E.A.; Puglisi, F.; Gianni, L. Treatment of HER2-positive breast cancer: Current status and future perspectives. *Nat. Rev. Clin. Oncol.* 2011, 9, 16–32. [CrossRef]

6. Romond, E.H.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E., Jr.; Davidson, N.E.; Tan-Chiu, E.; Martin, S.; Paik, S.; Kaufman, P.A.; et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N. Engl. J. Med.* 2005, 353, 1673–1684. [CrossRef]

7. Swain, S.M.; Baselga, J.; Kim, S.B.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.M.; Schneeweiss, A.; Heeson, S.; et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N. Engl. J. Med.* 2015, 372, 724–734. [CrossRef]

8. Wolff, A.C.; Hammond, M.E.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.; Bilous, M.; Fitzgibbons, P.; et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Arch. Pathol. Lab. Med.* 2014, 138, 241–256. [CrossRef]

9. Moreno-Aspitia, A.; Hillman, D.W.; Dyrar, S.H.; Tenner, K.S.; Gralow, J.; Kaufman, P.A.; Davidson, N.E.; Lafiisky, J.M.; Reinholz, M.M.; Lingle, W.L.; et al. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831. *Cancer* 2013, 119, 2675–2682. [CrossRef] [PubMed]

10. Lipton, A.; Leitzel, K.; Ali, S.M.; Carney, W.; Platek, G.; Steplewski, K.; Westlund, R.; Gagnon, R.; Martin, A.M.; Maltzman, J. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. *Cancer* 2011, 117, 5013–5020. [CrossRef]

11. Carney, W.P.; Neumann, R.; Lipton, A.; Leitzel, K.; Ali, S.; Price, C.P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. *Clin. Chem.* 2003, 49, 1579–1598. [CrossRef]
12. Christianson, T.A.; Doherty, J.K.; Lin, Y.J.; Ramsey, E.E.; Holmes, R.; Keenan, E.J.; Clinton, G.M. NH²-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998, 58, 5123–5129.

13. Reix, N.; Malina, C.; Chenard, M.P.; Bellocq, J.P.; Delpous, S.; Moielle, S.; Sevrin, A.; Neuberger, K.; Tomasetto, C.; Mathelin, C. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression. Breast Cancer Res. Treat. 2016, 160, 249–259. [CrossRef]

14. Tsé, C.; Gauchez, A.S.; Jacot, W.; Lamy, P.J. HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. Cancer Treat. Rev. 2012, 38, 136–142. [CrossRef]

15. Leyland-Jones, B.; Smith, B.R. Serum HER2 testing in patients with HER2-positive breast cancer: The death knell tolls. Lancet Oncol. 2011, 12, 286–295. [CrossRef]

16. Wang, T.; Zhou, J.; Zhang, S.; Bian, L.; Hu, H.; Xu, C.; Hao, X.; Liu, B.; Ye, Q.; Liu, Y.; et al. Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background, and serves several functions in the efficient management of breast cancer patients. Clin. Chim. Acta Int. J. Clin. Chem. 2016, 458, 23–29. [CrossRef]

17. Darlix, A.; Lamy, P.J.; Lopez-Crèpeau, E.; Braccini, A.L.; Finrin, N.; Romieu, G.; Thezenas, S.; Jacot, W. Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer 2016, 16, 428. [CrossRef]

18. Leary, A.F.; Hanna, W.M.; van de Vijver, M.J.; Penault-Llorca, F.; Rüschhoff, J.; Osamura, R.Y.; Bilous, M.; Dowsett, M. Value and limitations of measuring HER2 in the serum of breast cancer patients. J. Clin. Oncol. 2009, 27, 1694–1705. [CrossRef]

19. Zhang, Z.; Li, C.; Fan, H.; Xiang, Q.; Xu, L.; Liu, Q.; Zhou, S.; Xie, Q.; Chen, S.; Mu, G.; et al. Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: A systematic review and meta-analysis. Breast Cancer Res. Treat. 2018, 172, 513–521. [CrossRef] [PubMed]

20. Carney, W.P.; Bernhardt, D.; Jasani, B. Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients? Biomark. Cancer 2013, 5, 31–39. [CrossRef]

21. McInnes, M.D.F.; Moher, D.; Thomsen, B.D.; McGrath, T.A.; Bossuyt, P.M.; Clifford, T.; Cohen, J.F.; Deeks, J.J.; Gatsonis, C.; Hooft, L.; et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA 2018, 319, 388–396. [CrossRef]

22. Wells, G. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed on 17 August 2022).

23. Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [CrossRef] [PubMed]

24. Duval, S.; Tweedie, R. “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis. Biometrics 2000, 56, 276–284. [CrossRef]

25. Colomer, R.; Llombart-Cussac, A.; Lloveras, B.; Ramos, M.; Mayordomo, J.I.; Fernandez, R.; Tusquets, I.; Gil, M.; Barnadas, A.; Constenla, M.; et al. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: A confirmatory prospective study. Cancer 2007, 110, 2178–2185. [CrossRef]

26. Banys-Paluchowski, M.; Witzel, I.; Riethdorf, S.; Rack, B.; Janni, W.; Fasching, P.A.; Solomayer, E.F.; Aktas, B.; Kasimir-Bauer, S.; Pantel, K.; et al. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. Anticancer Res. 2017, 37, 3117–3128. [PubMed]

27. Lipton, A.; Ali, S.M.; Leitzel, K.; Demers, L.; Harvey, H.A.; Chaudri-Ross, H.A.; Brady, C.; Wyld, P.; Carney, W. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J. Clin. Oncol. 2003, 21, 1967–1972. [CrossRef] [PubMed]

28. Sandri, M.T.; Johansson, H.; Colleoni, M.; Zorrino, L.; Passerini, R.; Orlando, L.; Viale, G. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res. 2004, 24, 1261–1266. [PubMed]

29. Tchou, J.; Lam, L.; Li, Y.R.; Edwards, C.; Ky, B.; Zhang, H. Monitoring serum HER2 levels in breast cancer patients. SpringerPlus 2015, 4, 237. [CrossRef]

30. Baric, M.; Kulic, A.; Sirokovic-Skerlev, M.; Dedic, P.; Vidovic, M.; Horvatic-Herceg, G.; Vrbanec, D. Circulating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, HER-2/neu receptor coexpression. Pathol. Oncol. Res. 2015, 21, 589–595. [CrossRef] [PubMed]

31. Shao, X.; Wang, X.; Xu, X.; Feng, J.; Han, M.; Zhang, H.; Chen, Z.H.; Wang, S.; Zang, Y.M.; Huang, P.; et al. Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer. Int. J. Clin. Exp. Pathol. 2014, 7, 1108–1113. [PubMed]

32. Eppenberger-Castori, S.; Klingbiel, D.; Ruhstaller, T.; Dietrich, D.; Ruffe, D.A.; Rothgiesser, K.; Pagani, O.; Thurlimann, B. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study—SAKK 22/99. BMC Cancer 2020, 20, 114. [CrossRef]

33. Jensen, B.V.; Johansen, J.S.; Price, P.A. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin. Cancer Res. 2003, 9, 4423–4434.
44. Lipton, A.; Ali, S.M.; Leitzel, K.; Demers, L.; Chinchilli, V.; Engle, L.; Harvey, H.A.; Brady, C.; Nalin, C.M.; Dugan, M.; et al. Docetaxel plus

45. Cameron, D.; Casey, M.; Press, M.; Lindquist, D.; Pienkowski, T.; Romieu, C.G.; Chan, S.; Jagiello-Gruszfeld, A.; Kaufman, B.;

46. Kong, Y.; Dai, S.; Xie, X.; Xiao, X.; Lv, N.; Guo, J.; Li, L.; Jia, W.; Zhang, Y.; Liu, W.; et al. High serum HER2 extracellular domain levels: Correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J. Cancer Res. Clin. Oncol. 2012, 138, 275–284. [CrossRef]

47. Esteva, F.J.; Valero, V.; Boozer, D.; Guerra, L.T.; Murray, J.L.; Pusztai, L.; Cristofanilli, M.; Arun, B.; Esmaeili, B.; Fritsche, H.A.; et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 2002, 20, 1467–1472. [CrossRef]

48. Finn, R.S.; Gagnon, R.; Di Leo, A.; Press, M.F.; Arbushites, M.; Koehler, M. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J. Clin. Oncol. 2009, 27, 5552–5558. [CrossRef]

49. Muller, V.; Witzel, I.; Luck, H.J.; Kohler, G.; Minckwitz, G.; Mobus, V.; Sattler, D.; Wilczak, W.; Loning, T.; Janicke, F.; et al. Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res. Treat. 2004, 86, 9–18. [CrossRef]

50. Ryu, D.W.; Lee, C.H. Impact of Serum HER2 Levels on Survival and Its Correlation with Clinicopathological Parameters in Women with Breast Cancer. J. Breast Cancer 2012, 15, 71–78. [CrossRef]

51. Thureau, S.; Clatot, F.; Laberge-Le-Couteulx, S.; Baron, M.; Basuyau, J.P.; Blot, E. Elevated HER2 extracellular domain level in primary breast cancer with HER2 overexpression predicts early failure of adjuvant trastuzumab. Anticancer Res. 2012, 32, 1429–1433.

52. Colomer, R.; Llombart-Cussac, A.; Lluch, A.; Barnadas, A.; Ojeda, B.; Caranana, V.; Fernandez, Y.; Garcia-Conte, J.; Alonso, S.; Montero, S.; et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain. Ann. Oncol. 2004, 15, 201–206. [CrossRef]
53. Lüftner, D.; Henschke, P.; Flath, B.; Akrivakis, C.; Schnabel, S.; Prinz, B.; Geppert, R.; Wernecke, K.D.; Possinger, K. Serum HER-2/neu as a Prediction and Monitoring Parameter in a Phase II Study with Weekly Paclitaxel in Metastatic Breast Cancer. *Anticancer Res.* 2004, 24, 895–906.

54. Knutson, K.L.; Clynes, R.; Shreeder, B.; Yeramian, P.; Kemp, K.P.; Ballman, K.; Tenner, K.S.; Erskine, C.L.; Norton, N.; Northfelt, D.; et al. Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. *Cancer Res.* 2016, 76, 3702–3710. [CrossRef]

55. Tsai, H.-P.; Chen, S.-C.; Chien, H.-T.; Jan, Y.-Y.; Chao, T.-C.; Chen, M.-F.; Hsieh, L.-L. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer. *World J. Surg. Oncol.* 2012, 10, 42. [CrossRef]

56. Lee, S.B.; Lee, J.W.; Yu, J.H.; Ko, B.S.; Kim, H.J.; Son, B.H.; Gong, G.; Lee, H.J.; Kim, S.B.; Jung, K.H.; et al. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. *BMC Cancer* 2014, 14, 929. [CrossRef]

57. Bramwell, V.H.; Doig, G.S.; Tuck, A.B.; Wilson, S.M.; Tonkin, K.S.; Tomiak, A.; Perera, F.; Vandenberg, T.A.; Chambers, A.F. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. *Breast Cancer Res. Treat.* 2009, 114, 503–511. [CrossRef]

58. Bewick, M.; Conlon, M.; Gerard, S.; Lee, H.; Parissenti, A.M.; Zhang, L.; Gluck, S.; Lafrenie, R.M. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. *Bone Marrow Transplant.* 2001, 27, 847–853. [CrossRef]

59. Di Gioia, D.; Dresse, M.; Mayr, D.; Nagel, D.; Heinemann, V.; Stieber, P. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. *Clin. Chim. Acta* 2015, 440, 16–22. [CrossRef]

60. Colomer, R.; Montero, S.; Lluch, A.; Ojeda, B.; Barnadas, A.; Casado, A.; Massuti, B.; Cortes-Funes, H.; Lloveras, B. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. *Clin. Cancer Res.* 2000, 6, 2356–2362.

61. Lipton, A.; Leitzel, K.; Ali, S.; Carney, W.; Platek, G.; O’Rourke, L.; Martin, A.M.; Maltzman, J. Decrease in serum extracellular domain of HER2 at 4 and 8 weeks is associated with prolonged progression-free survival on lapatinib monotherapy. *Cancer Res.* 2009, 69, 244s. [CrossRef]

62. Lee, C.K.; Davies, L.; Gebski, V.J.; Lord, S.J.; Di Leo, A.; Johnston, S.; Geyer, C., Jr.; Cameron, D.; Press, M.E.; Ellis, C.; et al. Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. *J. Clin. Oncol.* 2016, 34, 936–944. [CrossRef]